Physician profile
Helen Paslay
NPI 1326431214
$2,474.30
in general payments reported to CMS, 2019-2025
26 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $676 · 2022: $837 · 2023: $265 · 2024: $541 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922 · Entertainment: $38.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.48 |
| Entertainment | $38.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $608.21 | 2021-2025 | Octrode, Proclaim |
| Lilly USA, LLC | $326.55 | 2021-2024 | Mounjaro, Zepbound |
| Amgen INC. | $315.94 | 2021-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $246.53 | 2022-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $148.71 | 2024-2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $122.17 | 2022 | |
| Lundbeck LLC | $82.99 | 2024 | Rexulti |
| Si-Bone, INC. | $82.58 | 2021-2022 | |
| Exact Sciences Corporation | $82.14 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $52.01 | 2023 | |
| Stryker Corporation | $42.89 | 2021 | |
| Pfizer INC. | $41.80 | 2024 | |
| Optos, INC. | $38.00 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Tactile Systems Technology INC | $36.20 | 2022 | |
| Glaxosmithkline, LLC. | $30.53 | 2022-2024 | Trelegy Ellipta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $26.80 | 2021 | |
| Boston Scientific Corporation | $25.63 | 2022 | |
| Allergan, INC. | $25.06 | 2021 | |
| Daiichi Sankyo INC. | $24.81 | 2021 | |
| Orthofix Medical, INC. | $20.01 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.34 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.31 | 2023 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $17.01 | 2021 | |
| Eisai INC. | $15.43 | 2021 | |
| Seqirus USA INC | $14.58 | 2024 | Fluad, Flucelvax |
| Biohaven Pharmaceutical Holding Company LTD. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Paslay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.